The Chinese company Sinopharm revealed that its second coronavirus vaccine, which is manufactured at the Wuhan Institute for Biological Products, achieved an efficacy rate of 72.5%, and according to a report by the South China Post newspaper, the Wuhan Institute for Biological Products announced months after the third phase of clinical trials in several countries around the world. It is the first time that the company has published such data.
On the other hand, the Chinese company Cansino said that the interim analysis of the results of vaccine trials in the final stage showed that their effectiveness rate is more than 65%, and the two companies now hope to obtain approval for their vaccines for public use in China, after they submitted applications this week to the National Medical Products Administration. .
Products made by Sinopharma's Beijing unit and Sinovac Biotech have already been given the green light for general use in China, while the Cansino vaccine has been approved for emergency use in Tianjin in several other countries, including Mexico and Pakistan.
The Sinovac vaccine was approved for general use in China this month, where it was previously found to be 50.6% effective in preventing corona virus in an experiment involving health care workers in Brazil, but it was 91% effective in a much smaller trial conducted in Turkey. .
The state-owned company Sinopharm is looking to become the first company to obtain approval for two coronavirus vaccines, after it received the green light for the first time in December.
Comments
Post a Comment